Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
14 Février 2024 - 2:03PM
Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a
commercial-stage, patient-centric biopharmaceutical company focused
on in-licensing, developing, and commercializing novel high-quality
medicines for patients living with rare diseases, today announced
that it will release its fourth quarter and full-year 2023
financial results after the market close on February 28, 2024.
Catalyst's management team will host a
conference call and webcast the following morning, Thursday,
February 29, 2024, at 8:30 AM ET, to discuss the Company's
financial results and provide a business update.
Conference Call & Webcast
Details |
Date: |
February 29,
2024 |
Time: |
8:30 AM ET |
US/Canada Dial-in Number: |
(877) 407-8912 |
International Dial-in Number: |
(201) 689-8059 |
|
|
A webcast and accompanying materials will be
accessible under the Investors section on the Company's website at
www.catalystpharma.com. A webcast replay will be available on the
Catalyst website for 30 days following the date of the event.
About Catalyst
PharmaceuticalsWith exceptional patient focus, Catalyst is
committed to developing and commercializing innovative
first-in-class medicines that address rare neurological and
epileptic diseases. Catalyst's flagship U.S. commercial
product is FIRDAPSE® (amifampridine) Tablets 10 mg, approved
for the treatment of Lambert-Eaton myasthenic syndrome ("LEMS") for
adults and for children ages six to seventeen. In January
2023, Catalyst acquired the U.S. commercial rights to
FYCOMPA® (perampanel) CIII, a prescription medicine approved
in people with epilepsy aged four and older alone or with other
medicines to treat partial-onset seizures with or without
secondarily generalized seizures and with other medicines to treat
primary generalized tonic-clonic seizures for people with epilepsy
aged 12 and older. Further, Canada's national healthcare
regulatory agency, Health Canada, has approved the use of
FIRDAPSE for the treatment of adult patients
in Canada with LEMS. Finally, on July 18, 2023,
Catalyst acquired an exclusive license for North
America for AGAMREE® (vamorolone) oral suspension 40
mg/mL, a novel corticosteroid treatment for Duchenne Muscular
Dystrophy. AGAMREE® previously received FDA Orphan Drug
and Fast Track designations and was approved for commercialization
in the U.S. on October 26, 2023.
For more information about Catalyst
Pharmaceuticals, Inc., please visit the Company's website
at www.catalystpharma.com. For Full Prescribing and Safety
Information for FIRDAPSE®, please visit www.firdapse.com. For Full
Prescribing Information, including Boxed WARNING for FYCOMPA®,
please visit www.fycompa.com. For Full Prescribing Information for
AGAMREE®, please visit www.agamree.com.
Forward-Looking StatementsThis
press release contains forward-looking statements, as that term is
defined in the Private Securities Litigation Reform Act of 1995.
These include statements regarding Catalyst’s expectations,
beliefs, plans, or objectives regarding the intended use of net
proceeds therefrom. Forward-looking statements involve known and
unknown risks and uncertainties, which may cause Catalyst's actual
results in future periods to differ materially from forecasted
results. A number of factors, including those factors described in
Catalyst's Annual Report on Form 10-K for the fiscal year 2022 and
its other filings with the U.S. Securities and Exchange
Commission ("SEC"), could adversely affect Catalyst. Copies of
Catalyst's filings with the SEC are available from
the SEC, may be found on Catalyst's website, or may be
obtained upon request from Catalyst. Catalyst does not undertake
any obligation to update the information contained herein, which
speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
Investor Contact
Mary Coleman, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
mcoleman@catalystpharma.com
Media Contact
David Schull, Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024